HA
CDAK

HHLR Advisors’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

HHLR Advisors’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-142,978
Closed -$2.33M – 86
2021
Q3 		$2.33M Sell
142,978
-223,743
-61% -$4M 0.03% 78
2021
Q2 		$6.79M Hold
366,721
– – 0.07% 74
2021
Q1 		$5.53M Hold
366,721
– – 0.05% 74
2020
Q4 		$11.8M Buy
+366,721
New +$4.85M 0.09% 69

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

HHLR Advisors's CDAK Position: Q4 2021 in Review

HHLR Advisors sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q4 2021, closing a stake of 142,978 shares — an estimated $2.33M sold.

HHLR Advisors first reported a position in CDAK in Q4 2020 and held it in 4 quarters. The position peaked at $11.8M in Q4 2020. 51 funds tracked by Wall St. Rank hold CDAK as of Q4 2021.

  • HHLR Advisors reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • HHLR Advisors sold 142,978 Codiak BioSciences, Inc. Common Stock shares in Q4 2021, an estimated $2.33M.
  • HHLR Advisors first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • HHLR Advisors's Codiak BioSciences, Inc. Common Stock position peaked at $11.8M in Q4 2020.
  • 51 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q4 2021.

Based on HHLR Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.